Business Context and Reporting Period
This Form 8-K Current Report was filed by Genpact Limited, a Bermuda-incorporated company, on March 27, 2014. The report discloses a corporate governance event regarding the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and board appointments.
Material Changes
The primary material change reported is the appointment of Hanspeter Spek to the Board of Directors, effective March 27, 2014. Mr. Spek, age 64, brings extensive experience from the pharmaceutical industry, having previously served as President of Global Operations at Sanofi S.A. and holding senior roles at Pfizer.
Compensation and Management Commentary
Under the Company's compensation program for non-employee directors, Mr. Spek's remuneration package includes:
- An annual retainer of $62,500.
- A sign-on grant of restricted share units valued at $180,000.
- An annual grant of restricted share units valued at $120,000.
The filing contains no forward-looking guidance, risk factors, or contingencies beyond the standard disclosure of the appointment.
Investor Verification Checklist
- Verify the effective date of Hanspeter Spek's board appointment (March 27, 2014).
- Confirm the total initial equity value granted ($180,000 sign-on + $120,000 annual grant).
- Review the Company's proxy statement for the full composition of the Board and voting procedures.
- Check subsequent filings for any changes to the compensation structure or additional board appointments.